Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharmacol ; 58(2): 253-62, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10908292

ABSTRACT

Retigabine is a novel anticonvulsant with an unknown mechanism of action. It has recently been reported that retigabine modulates a potassium channel current in nerve growth factor-differentiated PC12 cells (), however, to date the molecular correlate of this current has not been identified. In the present study we have examined the effects of retigabine on recombinant human KCNQ2 and KCNQ3 potassium channels, expressed either alone or in combination in Xenopus oocytes. Application of 10 microM retigabine to oocytes expressing the KCNQ2/3 heteromeric channel shifted both the activation threshold and voltage for half-activation by approximately 20 mV in the hyperpolarizing direction, leading to an increase in current amplitude at test potentials between -80 mV and +20 mV. Retigabine also had a marked effect on KCNQ current kinetics, increasing the rate of channel activation but slowing deactivation at a given test potential. Similar effects of retigabine were observed in oocytes expressing KCNQ2 alone, suggesting that KCNQ2 may be the molecular target of retigabine. Membrane potential recordings in oocytes expressing the KCNQ2/3 heteromeric channel showed that application of retigabine leads to a concentration-dependent hyperpolarization of the oocyte, from a resting potential of -63 mV under control conditions to -85 mV in the presence of 100 microM retigabine (IC(50) = 5.2 microM). In control experiments retigabine had no effect on either resting membrane potential or endogenous oocyte membrane currents. In conclusion, we have shown that retigabine acts as a KCNQ potassium channel opener. Because the heteromeric KCNQ2/3 channel has recently been reported to underlie the M-current, it is likely that M-current modulation can explain the anticonvulsant actions of retigabine in animal models of epilepsy.


Subject(s)
Anticonvulsants/pharmacology , Carbamates/pharmacology , Phenylenediamines/pharmacology , Potassium Channels/metabolism , Animals , CHO Cells , Cricetinae , Electrophysiology , Humans , KCNQ2 Potassium Channel , KCNQ3 Potassium Channel , Oocytes/drug effects , Oocytes/metabolism , Oocytes/physiology , Patch-Clamp Techniques , Potassium Channels/drug effects , Potassium Channels, Voltage-Gated , Transfection , Xenopus
2.
Br J Pharmacol ; 128(5): 1011-20, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10556938

ABSTRACT

1. The cellular and molecular actions of BW534U87 were studied using intracellular and extracellular recordings from the CA1 region of rat hippocampal slices and whole-cell voltage-clamp recordings of recombinant human brain type IIA Na+ channels expressed in Chinese hamster ovary (CHO) cells. 2. Normal excitatory and inhibitory postsynaptic potentials evoked in hippocampal slices were unaffected by BW534U87 or the adenosine deaminase inhibitor EHNA. However, epileptiform activity was depressed by BW534U87 (50 micronM) and this inhibition was reversed by the adenosine receptor antagonist 8-phenyl theophylline (8-PT, 30 micronM). EHNA (10 micronM) mimicked the effects of BW534U87. Furthermore, BW534U87 enhanced the inhibitory effects of exogenous adenosine on evoked synaptic potentials. BW534U87 (50 micronM) also voltage- and use-dependently inhibited action potentials elicited by current injection, independent of the adenosine system, since it was not affected by 8-PT. 3. In CHO cells expressing the recombinant human brain Na+ channel, BW534U87 produced a concentration- and voltage-dependent inhibition of Na+ currents with a half-maximal inhibitory concentration of 10 micronM at a Vh of -60 mV. Use-dependent inhibition was evident at high-frequencies (20x20 ms pulse train at 10 Hz). 4 In conclusion, BW534U87 blocks hippocampal epileptiform activity by a dual mechanism. The first action is similar to that produced by EHNA and is dependent on endogenous adenosine probably by inhibition of adenosine deaminase. Secondly, BW534U87 directly inhibits voltage-gated Na+ channels in a voltage- and frequency-dependent manner. Both actions of BW534U87 are activity-dependent and may synergistically contribute to its overall anticonvulsant effects in animal models of epilepsy.


Subject(s)
Adenosine/physiology , Anticonvulsants/pharmacology , Epilepsy/drug therapy , Hippocampus/physiopathology , Sodium Channels/physiology , Triazoles/pharmacology , Action Potentials/drug effects , Adenine/analogs & derivatives , Adenine/pharmacology , Adenosine Deaminase Inhibitors , Animals , Brain Chemistry/drug effects , CHO Cells , Cricetinae , Electrophysiology , Enzyme Inhibitors/pharmacology , Epilepsy/physiopathology , Female , Hippocampus/drug effects , In Vitro Techniques , Ion Channel Gating/drug effects , Magnesium/physiology , Male , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , Sodium Channels/drug effects
3.
Neuropharmacology ; 35(1): 1-11, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8684589

ABSTRACT

Synthetic funnel web spider toxin (sFTX-3.3) is a polyamine amide analogue of FTX, a toxin fraction isolated from the venom of the funnel web spider, Agelenopsis aperta, that blocks P-type Ca2+ channels. The structures of these polyamine containing compounds are not identical: sFTX-3.3 contains an amide carbonyl oxygen that is absent from the predicted structure of native FTX. Recently, a compound called FTX-3.3 was synthesized with the structure predicted for native FTX. We have compared the effects of polyamine amide sFTX-3.3 and polyamine FTX-3.3, on Ca2+ channel currents in the soma of mature rat cerebellar Purkinje neurons, in which the predominant Ca2+ channels are defined as P-type. Differential inhibition by sFTX-3.3 and FTX-3.3 revealed three populations of Ca2+ channels. One group, mediating approximately 66% of the current, was blocked by sFTX-3.3 with an IC50 (concentration producing half maximal inhibition) of 33 nM or by FTX-3.3 with an IC50 of 55 pM. A second population (5-25% of the total current) was inhibited by sFTX-3.3 with an IC50 of 33 nM, but was insensitive to FTX-3.3, while a third (10-30%) was blocked by FTX-3.3 with an IC50 of 125 nM and was resistant to sFTX-3.3. These channels also showed distinctive current-voltage relationships. Our results suggest that P-type Ca2+ channels in mature rat cerebellar Purkinje cells may be subdivided according to pharmacological and biophysical properties.


Subject(s)
Calcium Channels/drug effects , Purkinje Cells/drug effects , Spider Venoms/pharmacology , Animals , Dose-Response Relationship, Drug , Male , Membrane Potentials/drug effects , Rats , Rats, Wistar
4.
J Neurochem ; 65(1): 160-9, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7790857

ABSTRACT

GT1-7 cells, a clonal line derived from specific tumours of gonadotropin-releasing hormone-secreting neurons from mouse hypothalamus, were used as a model system to investigate the cellular mechanisms underlying the histamine H1 receptor-mediated desensitisation. GT1-7 cells contain H1 receptors, acute stimulation of which leads to the desensitisation of histamine-mediated calcium mobilisation and is manifest as a concurrent reduction in both the magnitude of the calcium transient and of the sustained phase. Acute pretreatment of the cells with the phorbol ester, phorbol 12-myristate 13-acetate, can also ablate the histamine-stimulated calcium mobilisation. In addition, acute H1-receptor stimulation and acute phorbol ester treatment result in the attenuation of histamine-mediated inositol phosphate production. Receptor desensitisation resulting from acute stimulation with histamine is not affected by inhibiting protein kinase C (PKC) activity with Ro 31-7549 or staurosporine. In contrast, the desensitisation of H1-receptor responses induced by direct activation of protein kinase C is preventable by PKC inhibitors. Thus, these results imply that a PKC-dependent mechanism and PKC-independent mechanism are involved in the H1-receptor desensitisation cascade in GT1-7 cells and do not support the involvement of PKC in the receptor-mediated desensitisation of H1 receptor-stimulated calcium and inositol phosphate responses.


Subject(s)
Calcium/metabolism , Inositol Phosphates/biosynthesis , Neurons/metabolism , Protein Kinase C/physiology , Receptors, Histamine H1/physiology , Animals , Biological Transport , Calcium/agonists , Histamine/physiology , Intracellular Membranes/metabolism , Mice , Osmolar Concentration , Protein Kinase C/antagonists & inhibitors , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured
5.
Neurosci Lett ; 178(1): 159-62, 1994 Aug 29.
Article in English | MEDLINE | ID: mdl-7529386

ABSTRACT

Histamine, acting via H1 receptors, dose-dependently stimulated [3H]inositol phosphate production in GT1-7 neuronal cells. GT1-7 cells also responded to Substance P but not to other neuroactive drugs tested. Acute histamine pretreatment desensitised the histamine-induced response, resulting in a reduction in the maximal response and a slower time-course of [3H]-inositol phosphate production. The desensitisation phenomenon was reversible, with full recovery by 2 h.


Subject(s)
Histamine/pharmacology , Neurons/metabolism , Receptors, Histamine H1/physiology , Substance P/pharmacology , Animals , Carbachol/pharmacology , Cell Line, Transformed , Dose-Response Relationship, Drug , Glutamic Acid/pharmacology , Histamine Antagonists , Histamine H1 Antagonists/pharmacology , Hypothalamus , Inositol Phosphates/metabolism , Kinetics , Mice , Neuropeptide Y/pharmacology , Piperidines/pharmacology , Pyrimidinones/pharmacology , Ranitidine/pharmacology , Receptors, Histamine H1/biosynthesis , Serotonin/pharmacology , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...